RETAIN-3 trial: what clinicians have said so far
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
- NCT07908979 ↗
- Recruiting
- Fox Chase Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on RETAIN-3 (enfortumab vedotin plus pembrolizumab; pembrolizumab in muscle-invasive bladder urothelial carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RETAIN-3 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- GU-254: A Phase II Trial of Risk-Enabled Therapy After Initiating Neoadjuvant Enfortumab Vedotin/Pembrolizumab for Bladder Cancer (RETAIN-3)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Bladder Cancer; Urothelial Carcinoma; Muscle-Invasive Bladder Carcinoma; Muscle-invasive Bladder Urothelial Carcinoma
- Interventions
- Enfortumab vedotin; Pembrolizumab; Cisplatin; Gemcitabine; Fluorouracil; Mitomycin c; Radical cystectomy; Radiation therapy
- Arms
- Arm A: Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab With Restaging · Experimental
- Arm B: Additional Enfortumab Vedotin Plus Pembrolizumab for ctDNA-Positive Participants · Experimental
- Arm C: Maintenance Pembrolizumab With Active Surveillance · Experimental
- Arm D: Definitive Chemoradiation · Experimental
- Arm E: Radical Cystectomy · Experimental
- Enrollment
- 70 (estimated)
- Primary outcomes
- 2-Year Metastasis-Free Survival (MFS)
- Sponsor
- Fox Chase Cancer Center with Natera, Inc.
- Start
- Oct 16, 2026
- Primary completion
- Oct 1, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07908979 · updated Nov 2, 2026